Benign prostatic hyperplasia: US-guided transrectal urethral enlargement with radio frequency--initial results in a canine model.

Goldberg, S. Nahum; Hahn, P F; McGovern, Francis J.; Fogle, R M; Müeller, Peter R.; Gazelle, G. Scott

doi:10.1148/radiology.208.2.9680581

Cited by 12 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we report on an experiment involving ILC in an in vivo canine prostate model. Canine prostate has topographical features comparable to the human prostate, and this study represents a logical preliminary stage before designing human prostate protocols (18, 19). One of the anticipated outcomes of this study was to determine whether quantitative MR‐thermal mapping can predict of thermal damage in the prostate, thereby providing useful operating parameters with which to conduct future human prostate studies.…”

mentioning

confidence: 99%

Magnetic resonance thermometry for predicting thermal damage: An application of interstitial laser coagulation in an in vivo canine prostate model

Chan²,

et al. 2000

View full text Add to dashboard Cite

mentioning

confidence: 99%

Magnetic resonance thermometry for predicting thermal damage: An application of interstitial laser coagulation in an in vivo canine prostate model

Chan²,

et al. 2000

View full text Add to dashboard Cite

“…Another preclinical study that showed promising results, but was never, to our knowledge, transferred into a published clinical study, was the work by Ahmed et al investigating the combination of RF ablation and lipo‐DOX . A few reports on the use of RF ablation as the sole treatment for dogs with non‐cancerous disease exist . However, the improved efficacy in the Ahmed study when combining RF with lipo‐DOX compared with either of the modalities, indicates that these methods should be employed together for cancer treatment.…”

Section: Primary Lessons From Canine and Feline Liposomal Chemotherapmentioning

confidence: 99%

Liposome‐encapsulated chemotherapy: Current evidence for its use in companion animals

Børresen

Hansen

Kjær

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

Cytotoxic drugs encapsulated into liposomes were originally designed to increase the anticancer response, while minimizing off-target adverse effects. The first liposomal chemotherapeutic drug was approved for use in humans more than 20 years ago, and the first publication regarding its use in a canine cancer patient was published shortly thereafter. Regardless, no general application for liposomal cytotoxic drugs has been established in veterinary oncology till now.Due to the popularity of canines as experimental models for pharmacokinetic analyses and toxicity studies, multiple publications exist describing various liposomal drugs in healthy dogs. Also, some evidence for its use in veterinary cancer patients exists, especially in canine lymphoma, canine splenic hemangiosarcoma and feline soft tissue sarcoma, however, the results have not been overwhelming. Reasons for this may be related to inherent issues with the enhanced permeability and retention effect, the tumour phenomenon which liposomal drugs exploit. This effect seems very heterogeneously distributed in the tumour. Also, it is potentially not as ubiquitously occurring as once thought, and it may prove important to select patients for liposomal therapy on an individual, non-histology-oriented, basis. Concurrently, new developments with active-release modified liposomes in experimental models and humans will likely be relevant for veterinary patients as well, and holds the potential to improve the therapeutic response. It, however, does not resolve the other challenges that liposomal chemotherapy faces, and more work still needs to be done to determine which veterinary patients may benefit the most from liposomal chemotherapy. K E Y W O R D Schemotherapy, liposomes, nanomedicine, oncology, small animal

show abstract

“…Minimally invasive therapies have gained increasing attention in the last decade as an alternative to standard surgical therapy (Hill and ter Haar 1995, Murphy and Gill 2001, Chin and Pautler 2002, Goldberg and Ahmed 2002, Ogan and Cadeddu 2002, Tunuguntla and Evans 2002. They are being investigated for the treatment of many diseases such as primary hepatocellular carcinoma (HCC) (Goldberg 2001, Haemmerich et al 2001, Goldberg and Ahmed 2002, lower urinary tract symptoms due to benign prostatic hyperplasia (Goldberg et al 1998, Beerlage et al 2000, Tunuguntla and Evans 2002 and small renal-cell carcinoma (RCC) (Gervais et al 2000, Murphy and Gill 2001, Chin and Pautler 2002, Ogan and Cadeddu 2002. Temperatures greater than 42 • C are considered potentially lethal, depending on the duration of application (Rosner et al 1996), and temperatures greater than 60 • C are associated with uniform tissue necrosis.…”

Section: Introductionmentioning

confidence: 99%

Dynamic frame selection forin vivoultrasound temperature estimation during radiofrequency ablation

Daniels

Varghese

2010

Phys. Med. Biol.

View full text Add to dashboard Cite

Minimally invasive therapies such as radiofrequency ablation have been developed to treat cancers of the liver, prostate and kidney without invasive surgery. Prior work has demonstrated that ultrasound echo shifts due to temperature changes can be utilized to track the temperature distribution in real time. In this paper, a motion compensation algorithm is evaluated to reduce the impact of cardiac and respiratory motion on ultrasound-based temperature tracking methods. The algorithm dynamically selects the next suitable frame given a start frame (selected during the exhale or expiration phase where extraneous motion is reduced), enabling optimization of the computational time in addition to reducing displacement noise artifacts incurred with the estimation of smaller frame-to-frame displacements at the full frame rate. A region of interest that does not undergo ablation is selected in the first frame and the algorithm searches through subsequent frames to find a similarly located region of interest in subsequent frames, with a high value of the mean normalized cross-correlation coefficient value. In conjunction with dynamic frame selection, two different two-dimensional displacement estimation algorithms namely a block matching and multilevel cross-correlation are compared. The multi-level cross-correlation method incorporates tracking of the lateral tissue expansion in addition to the axial deformation to improve the estimation performance. Our results demonstrate the ability of the proposed motion compensation using dynamic frame selection in conjunction with the two-dimensional multilevel cross-correlation to track the temperature distribution.

show abstract

Benign prostatic hyperplasia: US-guided transrectal urethral enlargement with radio frequency--initial results in a canine model.

Abstract: Transrectal RF urethral enlargement is feasible and safe in animals and merits investigation for alleviating urethral obstruction due to benign prostatic hyperplasia.

Cited by 12 publications

References 0 publications

Magnetic resonance thermometry for predicting thermal damage: An application of interstitial laser coagulation in an in vivo canine prostate model

Magnetic resonance thermometry for predicting thermal damage: An application of interstitial laser coagulation in an in vivo canine prostate model

Liposome‐encapsulated chemotherapy: Current evidence for its use in companion animals

Dynamic frame selection forin vivoultrasound temperature estimation during radiofrequency ablation

Contact Info

Product

Resources

About